Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model

References

• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80. doi:10.1126/science.aaa6204
   PubMed Web of Science ®Google Scholar
• Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine. 2018;31:17–24. doi:10.1016/j.ebiom.2018.04.020
   PubMed Web of Science ®Google Scholar
• Koske I, Rossler A, Pipperger L, et al. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment. Int J Cancer. 2019;145(7):1958–1969. doi:10.1002/ijc.32325
   PubMed Web of Science ®Google Scholar
• Xu B, Ma R, Russell L, et al. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nat Biotechnol. 2018. doi:10.1038/nbt.4302
   Google Scholar
• Shi G, Yang Q, Zhang Y, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244–260. doi:10.1016/j.ymthe.2018.11.010
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290(26):1458–1469. doi:10.1056/NEJM197406272902605
   PubMed Web of Science ®Google Scholar
• Yamazaki-Nakashimada MA, Unzueta A, Berenise Gamez-Gonzalez L, Gonzalez-Saldana N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccin Immunother. 2020;16(8):1841–1850. doi:10.1080/21645515.2019.1706930
   PubMed Web of Science ®Google Scholar
• Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14(4):244–255. doi:10.1038/nrurol.2017.16
   PubMed Web of Science ®Google Scholar
• Tse J, Singla N, Ghandour R, Lotan Y, Margulis V. Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opin Investig Drugs. 2019;28(9):757–770. doi:10.1080/13543784.2019.1655730
   PubMed Web of Science ®Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–269. doi:10.1007/s00404-015-3859-y
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019;20(11):82. doi:10.1007/s11864-019-0682-x
   PubMed Web of Science ®Google Scholar
• Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957. doi:10.3390/cells8090957
   PubMed Web of Science ®Google Scholar
• Lyons TG, Traina TA. Emerging novel therapeutics in triple-negative breast cancer. Adv Exp Med Biol. 2019;1152:377–399.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Yang X, et al. Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer. Onco Targets Ther. 2018;11:2891–2899. doi:10.2147/OTT.S165840
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67. doi:10.1016/j.ctrv.2017.01.007
   PubMed Web of Science ®Google Scholar
• Wu Y, Enting D, Rudman S, Chowdhury S. Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Rev Anticancer Ther. 2015;15(5):509–523. doi:10.1586/14737140.2015.1015419
   PubMed Web of Science ®Google Scholar
• Ewels PA, Peltzer A, Fillinger S, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276–278. doi:10.1038/s41587-020-0439-x
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12). doi:10.1186/s13059-014-0550-8
   Web of Science ®Google Scholar
• Wang Q, Wang Y, Ding J, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–426. doi:10.1038/s41586-020-2079-1
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900e810. doi:10.1016/j.ccell.2019.05.004
   PubMed Web of Science ®Google Scholar
• Copland A, Sparrow A, Hart P, et al. Bacillus Calmette-Guerin induces PD-L1 expression on antigen-presenting cells via autocrine and paracrine interleukin-STAT3 circuits. Sci Rep. 2019;9(1):3655. doi:10.1038/s41598-019-40145-0
   PubMedGoogle Scholar
• Gouveia ACC, Braga FG, Mota M, et al. Enhanced expression of PD-L1 and IFN-gamma on dendritic cells is associated with BCG-induced Th2 inhibition. Cytokine. 2017;99:163–172. doi:10.1016/j.cyto.2017.09.005
   PubMed Web of Science ®Google Scholar
• Eich ML, Chaux A, Guner G, et al. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. Hum Pathol. 2019;89:24–32. doi:10.1016/j.humpath.2019.04.003
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234(10):16824–16837. doi:10.1002/jcp.28358
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.
   Web of Science ®Google Scholar
• Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol. 2000;164(2):526–531. doi:10.1016/S0022-5347(05)67417-4
   PubMed Web of Science ®Google Scholar